Theriva Sells SYN-004 Portfolio to Biossil for Up to $91M

Theriva Biologics, Inc. (NYSE American: TOVX) announced on 2 November 2026 that it sold its antibiotic-degrading enzyme portfolio — including SYN-004 (ribaxamase), SYN-007 (reformulated ribaxamase), and SYN-006 (carbapenemase) — to Toronto-based Biossil Labs Inc. Theriva received a $350,000 upfront payment at closing and is eligible for up to $3 million in regulatory milestones, up to $88 million tied to cumulative worldwide net sales thresholds, and low single-digit royalties capped at $250 million. Biossil assumes all future development and commercialization costs for the portfolio.

Context — Why the SYN-004 Sale Matters Now

The transaction marks Theriva's exit from the gastrointestinal microbiome-protecting enzyme space and concentrates the company's pipeline on its oncolytic adenovirus platform. The report states that with the sale, Theriva's lead product candidate becomes VCN-01, an oncolytic adenovirus designed to replicate selectively within tumor cells and degrade the tumor stroma barrier.

The company had invested significantly in SYN-004 clinical development, according to CEO Steven A. Shallcross, who said the portfolio could benefit patients and hospital systems by reducing infections from Clostridioides difficile, vancomycin-resistant enterococci (VRE), and carbapenem-resistant Enterobacterales (CRE).

The sale arrives as the Phase 1b/2a trial at Washington University School of Medicine in St. Louis remains paused after completing 2 of 3 cohorts. That trial evaluates SYN-004 in allogeneic hematopoietic cell transplant (HCT) recipients receiving IV beta-lactam antibiotics. Enrollment was paused with one cohort remaining, and the report does not state when or whether it will resume under Biossil.

Biossil is a privately held, AI-native biopharmaceutical company with teams in Toronto and Boston, advancing late-stage programs in life-threatening indications. The report describes partnerships with academic medical centers and research hospitals but does not name them or disclose financial terms beyond the headline figures.

Data — What the Deal Terms Show

The headline economics are heavily back-loaded. Theriva collects $350,000 at closing against a potential $91 million in combined regulatory and sales milestones — roughly 260 times the upfront payment. Of that total, $3 million is tied to regulatory milestones and $88 million to cumulative worldwide net sales thresholds.

Royalties are described as low single-digit on net product sales, subject to a $250 million cap. The report does not disclose the specific royalty rate, the sales thresholds that trigger milestone payments, or the timeline for either.

Component	Amount
Upfront payment	$350,000
Regulatory milestones	Up to $3,000,000
Sales milestones	Up to $88,000,000
Royalty cap	$250,000,000

The structure shifts development risk to Biossil. The report says Biossil assumed all responsibility and costs for future development and commercialization. For Theriva, that removes ongoing trial expense but also removes direct control over whether the assets reach market.

Clinical precedent cited in the report: a completed randomized, placebo-controlled Phase 2b trial in 412 patients receiving IV ceftriaxone for lower respiratory tract infection showed the SYN-004 treatment group had significantly better maintenance and recovery of the gut microbiome, a lower incidence of CDI, and reduced colonization by VRE. Preclinical proof-of-concept exists for SYN-007 in dogs and SYN-006 in a pig model.

Analysis — What It Means for Markets and Sectors

The deal's structure says as much about Theriva's capital position as about the asset's promise. A $350,000 upfront payment is small relative to the roughly $91 million in contingent consideration, meaning Theriva monetized optionality rather than near-term cash flow. The company did not disclose its cash balance or runway in the report.

For Biossil, the acquisition adds a clinical-stage asset with a completed Phase 2b dataset and an ongoing, paused Phase 1b/2a trial in a transplant population. The company's stated model integrates proprietary AI with clinical and translational expertise to advance clinical-stage assets, and chief scientific officer Alexander I. Mosa said gut dysbiosis, antibiotic-resistant colonization, and opportunistic infections in vulnerable patients represent important unmet needs.

The counter-argument is timing risk. The Phase 1b/2a trial is paused with one cohort incomplete, and the report does not identify a restart date or confirm Biossil's funding commitment to it. Milestone payments depend on regulatory approvals and net sales that require years of development and commercial execution.

Sector exposure sits in the antimicrobial resistance and microbiome space, where the report frames the portfolio's value around reducing CDI, VRE, and CRE infections and the incidence or severity of acute graft-versus-host disease (aGVHD). Erik R. Dubberke, Professor of Medicine at Washington University, said ribaxamase could improve outcomes after allogeneic HCT by preventing these infections and called the aGVHD potential a potential game-changer.

Positioning: the transaction is a small-cap, single-name event. The report provides no share price, volume, or market capitalization data, and no peer multiples, so relative valuation cannot be assessed from the disclosure alone.

Outlook — What to Watch Next

Three catalysts matter. First, whether the Phase 1b/2a trial at Washington University resumes enrollment into cohort 3, where patients receive IV cefepime, a substrate for SYN-004. The report gives no restart date.

Second, Biossil's development plan and funding for the portfolio, including whether it advances SYN-004 toward the regulatory milestones that unlock the $3 million tranche. The report does not describe Biossil's capital resources.

Third, Theriva's execution on VCN-01, now its lead candidate. The report notes VCN-01 completed a Phase 2b trial in first-line metastatic pancreatic cancer treated with gemcitabine-nab-paclitaxel, with results published in Nature Medicine, and that Theriva is in discussions with regulatory agencies about a potential Phase 2/3 trial in retinoblastoma.

No price levels, moving averages, or index thresholds are named in the report or supported by the disclosure, so none are cited here. Investors tracking TOVX should watch for filings describing cash position and VCN-01 timelines, which the report does not provide.

Frequently Asked Questions

What does the Theriva Biossil deal mean for retail investors?

The transaction converts a development-stage portfolio into contingent future payments rather than near-term revenue. Theriva receives $350,000 now and could receive up to $91 million if regulatory and sales milestones are met, plus capped royalties. Retail holders are exposed to Biossil's execution, since Theriva no longer funds or controls the portfolio's development. The report does not disclose Theriva's cash position, so the deal's impact on the company's runway cannot be determined from this disclosure.

What happens next for the SYN-004 clinical trial?

The Phase 1b/2a trial at Washington University School of Medicine in St. Louis has completed 2 of 3 cohorts and is currently paused. Cohort 3 would administer IV cefepime, a substrate for SYN-004. The report states Biossil assumed all responsibility and costs for future development, but does not say whether Biossil will restart enrollment, when, or under what protocol amendments. An independent Data and Safety Monitoring Committee previously recommended proceeding to cohort 3 after reviewing the first two cohorts.

Why is the royalty capped at $250 million?

The report states Theriva is eligible for low single-digit royalties on net product sales subject to a cap of $250 million, without explaining the rationale. Caps are common in asset sales because they limit the buyer's long-term payment obligation once cumulative royalties reach the threshold. The report does not disclose the specific royalty percentage, the sales levels needed to approach the cap, or the duration of the royalty term, so the practical value of this component depends on commercialization outcomes not described in the disclosure.

Bottom Line

Theriva has traded control of its antibiotic-degrading enzyme portfolio for $350,000 upfront and up to $91 million in contingent milestones, leaving Biossil to fund a paused trial.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.